

Drugs@FDA: FDA Approved Drug Products

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=204275\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204275)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=204275\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug Products&url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204275)

 [LINKEDIN \(HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=204275&TITLE=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&SOURCE=FDA\)](https://www.linkedin.com/sharearticle?mini=true&url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204275&title=Drugs@FDA: FDA Approved Drug Products&source=fda)

 [PIN IT \(HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON/?URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=204275&DESCRIPTION=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS\)](https://www.pinterest.com/pin/create/button/?url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204275&description=Drugs@FDA: FDA Approved Drug Products)



 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=204275\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204275)

 **PRINT**

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 204275

Company: GLAXO GRP LTD

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=204275\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process%26varapplno=204275)

[Products on NDA 204275](#)



[CSV](#) [Excel](#) [Print](#)

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
BREO ELLIPTA	FLUTICASONE FUROATE; VILANTEROL TRIFENATATE	0.1MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription	None	Yes	Yes
BREO ELLIPTA	FLUTICASONE FUROATE; VILANTEROL TRIFENATATE	0.2MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription	None	Yes	Yes

Showing 1 to 2 of 2 entries

[Approval Date\(s\) and History, Letters, Labels, Reviews for NDA 204275](#)[Labels for NDA 204275](#)